2:02 PM
 | 
Sep 13, 2018
 |  BC Extra  |  Company News

FDA approves AZ's hairy cell leukemia drug

FDA approved Lumoxiti moxetumomab pasudotox-tdfk from AstraZeneca plc (LSE:AZN; NYSE:AZN) to treat relapsed or refractory hairy cell leukemia in adults who have received at least two prior systemic therapies, including a purine nucleoside analog.

Lumoxiti, an anti-CD22 antibody variable fragment fused to the PE38 immunotoxin, has Orphan Drug status from FDA.

The drug's label includes a boxed warning about the risks of capillary leak syndrome and hemolytic uremic syndrome.

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

Purchase this article for limited one-time distribution and website posting

$750 USD